Femasys Inc (Nasdaq:FEMY), a biomedical innovator focused on addressing unmet needs in women's health, announced on Thursday that it has received Conformité Européene (CE) mark certification for its FemBloc delivery system, a non-surgical approach to permanent birth control for women.
This approval represents a significant milestone in the availability of FemBloc, which offers a minimally invasive, non-surgical alternative to traditional sterilisation methods.
The FemBloc system delivers a proprietary synthetic tissue adhesive to both fallopian tubes, creating non-functional scar tissue that permanently blocks the tubes. Over time, the blended polymer fully degrades.
The approval follows a successful G12 Special MDR Audit for Class III devices, with the European Medical Agency (EMA) expected to complete its review by mid-2025.
According to Femasys, its innovation provides a lower-cost, less risky option for permanent birth control, offering a significant advancement over surgical procedures.
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial